Heart Failure and Chronic Kidney Disease Manifestation and Mortality Risk -Associations in Type 2 Diabetes: A Large Multinational Cohort Study

被引:0
作者
Birkeland, K. I. [1 ,2 ]
Bodegard, J. [3 ]
Eriksson, J. W. [4 ]
Norhammar, A. [5 ,6 ]
Haller, H. [7 ]
Linssen, G. C. M. [8 ]
Banerjee, A. [9 ,10 ]
Thuresson, M. [11 ]
Okami, S. [12 ]
Garal-Pantaler, E. [13 ]
Overbeek, J. [14 ]
Mamza, J. B. [15 ]
Zhang, R. [15 ]
Yajima, T. [12 ]
Komuro, I. [16 ]
Kadowaki, T. [17 ,18 ]
机构
[1] Univ Klinikum Oslo, Oslo, Norway
[2] Univ Oslo, Oslo, Norway
[3] AstraZeneca, Oslo, Norway
[4] Uppsala Univ, Klin Diabet & Stoffwechsel, Abt Med Wissensch, Uppsala, Sweden
[5] Karolinska Inst, Kardiol Fachbereich Med Solna, Stockholm, Sweden
[6] Capio St Gorans Krankenhaus, Stockholm, Sweden
[7] Hannover Med Sch, Nephrol Abt, Hannover, Germany
[8] Abt Kardiol Krankenhausgruppe Twente, Hengelo, Niederlande
[9] Coll Univ London, Inst Gesundheitsinformat, London, England
[10] Krankenhauser Coll Univ London, Abt Kardiol, London, England
[11] Statisticon AB, Uppsala, Sweden
[12] AstraZeneca, Osaka, Japan
[13] Team Gesundheit GmbH, Essen, Germany
[14] PHARMO Inst Erforschung Arzneimittelwirkungen, Utrecht, Netherlands
[15] AstraZeneca, Luton, Beds, England
[16] Med Hsch Univ Tokio, Abt Kardiovask Med, Tokyo, Japan
[17] Hsch Med Univ Tokio, Abt Pravent Diabet & Lebensstilbedingten Erkrank, Tokyo, Japan
[18] Mizonokuchi Krankenhaus Teikyo Univ, Abt Metab & Ernahrung, Teikyo, Kanagawa, Japan
来源
DIABETES STOFFWECHSEL UND HERZ | 2021年 / 30卷 / 01期
关键词
diabetic nephropathy; heart failure; macrovascular disease; observational study; type; 2; diabetes; SGLT2; inhibitor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. Methods: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD-free status. Results: Of 1 177 896 patients with T2D, 772 336 (66 %) were CVRD-free and followed for a mean of 4.5 years. A total of 137081 patients (18 %) developed a first CVRD manifestation, represented by CKD (36 %), HF (24 %), stroke (16 %), MI (14 %) and PAD (10 %). HF or CKD was associated with increased cardiovascular and allcause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75 - 2.33) and HR 2.05 (95 % CI 1.82 - 2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all-cause mortality risk: HRs 3.91 (95 % CI 3.02 - 5.07) and 3.14 (95 % CI 2.90 - 3.40), respectively. Conclusion: In a large multinational study of > 750 000 CVRD-free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 58 条
  • [1] Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
    Afkarian, Maryam
    Sachs, Michael C.
    Kestenbaum, Bryan
    Hirsch, Irl B.
    Tuttle, Katherine R.
    Hinnmelfarb, Jonathan
    de Boer, Ian H.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (02): : 302 - 308
  • [2] The Population Burden of Heart Failure Attributable to Modifiable Risk Factors The ARIC (Atherosclerosis Risk in Communities) Study
    Avery, Christy L.
    Loehr, Laura R.
    Baggett, Christopher
    Chang, Patricia P.
    Kucharska-Newton, Anna M.
    Matsushita, Kunihiro
    Rosamond, Wayne D.
    Heiss, Gerardo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) : 1640 - 1646
  • [3] Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
    Basta, G
    Schmidt, AM
    De Caterina, R
    [J]. CARDIOVASCULAR RESEARCH, 2004, 63 (04) : 582 - 592
  • [4] Heart failure prevalence, incidence, and mortality in the elderly with diabetes
    Bertoni, AG
    Hundley, WG
    Massing, MW
    Bonds, DE
    Burke, GL
    Goff, DC
    [J]. DIABETES CARE, 2004, 27 (03) : 699 - 703
  • [5] How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
    Birkeland, Kare I.
    Bodegard, Johan
    Norhammar, Anna
    Kuiper, Josephina G.
    Georgiado, Elena
    Beekman-Hendriks, Wendy L.
    Thuresson, Marcus
    Pignot, Marc
    Herings, Ron M. C.
    Kooy, Adriaan
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (04) : 968 - 974
  • [6] Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
    Birkeland, Kare I.
    Jorgensen, Marit E.
    Carstensen, Bendix
    Persson, Frederik
    Gulseth, Hanne L.
    Thuresson, Marcus
    Fenici, Peter
    Nathanson, David
    Nystrom, Thomas
    Eriksson, Jan W.
    Bodegard, Johan
    Norhammar, Anna
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09) : 709 - 717
  • [7] Diabetes, heart failure, and renal dysfunction: The vicious circles
    Braunwald, Eugene
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2019, 62 (04) : 298 - 302
  • [8] CKD Prevalence Varies across the European General Population
    Bruck, Katharina
    Stel, Vianda S.
    Gambaro, Giovanni
    HaIlan, Stein
    Volzke, Henry
    Arnlov, Johan
    Kastarinen, Mika
    Guessous, Idris
    Vinhas, Jose
    Stengel, Benedicte
    Brenner, Hermann
    Chudek, Jerzy
    Romundstad, Solfrid
    Tomson, Charles
    Otero Gonzalez, Alfonso
    Bello, Aminu K.
    Ferrieres, Jean
    Palmieri, Luigi
    Browne, Gemma
    Capuano, Vincenzo
    Van Biesen, Wim
    Zoccali, Carmine
    Gansevoort, Ron
    Navis, Gerjan
    Rothenbacher, Dietrich
    Ferraro, Pietro Manuel
    Nitsch, Dorothea
    Wanner, Christoph
    Jager, Kitty J.
    Consortium, European C. K. D. Burden
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (07): : 2135 - 2147
  • [9] Diagnostic accuracy for heart failure- data from Akershus heart survey 2
    Brynildsen, Jon
    Hoiseth, Arne Didrik
    Nygard, Stale
    Hagve, Tor-Arne
    Christensen, Geir
    Omland, Torbjorn
    Rosjo, Helge
    [J]. TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2015, 135 (19) : 1738 - 1744
  • [10] Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus
    Cherney, David Z., I
    Repetto, Enrico
    Wheeler, David C.
    Arnold, Suzanne, V
    MacLachlan, Sharon
    Hunt, Philip R.
    Chen, Hungta
    Vora, Jiten
    Kosiborod, Mikhail
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (01) : 74 - 82